Melinta Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MELINTA
MELINTA has five approved drugs.
There are seventeen US patents protecting MELINTA drugs.
Summary for Melinta
| US Patents: | 17 |
| Tradenames: | 4 |
| Ingredients: | 3 |
| NDAs: | 5 |
| Patent Litigation for Melinta: | See patent lawsuits for Melinta |
Drugs and US Patents for Melinta
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | RX | Yes | Yes | 12,514,899 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Melinta Therap | TOPROL-XL | metoprolol succinate | TABLET, EXTENDED RELEASE;ORAL | 019962-002 | Jan 10, 1992 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Melinta | BAXDELA | delafloxacin meglumine | POWDER;INTRAVENOUS | 208611-001 | Jun 19, 2017 | RX | Yes | Yes | 8,273,892 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Melinta Therap | TOPROL-XL | metoprolol succinate | TABLET, EXTENDED RELEASE;ORAL | 019962-003 | Jan 10, 1992 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Melinta | BAXDELA | delafloxacin meglumine | TABLET;ORAL | 208610-001 | Jun 19, 2017 | RX | Yes | Yes | 8,273,892 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Melinta | BAXDELA | delafloxacin meglumine | POWDER;INTRAVENOUS | 208611-001 | Jun 19, 2017 | RX | Yes | Yes | 7,635,773 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Melinta | BAXDELA | delafloxacin meglumine | POWDER;INTRAVENOUS | 208611-001 | Jun 19, 2017 | RX | Yes | Yes | 8,871,938 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Melinta
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Melinta | BAXDELA | delafloxacin meglumine | TABLET;ORAL | 208610-001 | Jun 19, 2017 | 8,273,892 | ⤷ Start Trial |
| Melinta Therap | TOPROL-XL | metoprolol succinate | TABLET, EXTENDED RELEASE;ORAL | 019962-003 | Jan 10, 1992 | 3,998,790 | ⤷ Start Trial |
| Melinta | BAXDELA | delafloxacin meglumine | POWDER;INTRAVENOUS | 208611-001 | Jun 19, 2017 | 8,273,892 | ⤷ Start Trial |
| Melinta | BAXDELA | delafloxacin meglumine | TABLET;ORAL | 208610-001 | Jun 19, 2017 | 8,969,569 | ⤷ Start Trial |
| Melinta Therap | TOPROL-XL | metoprolol succinate | TABLET, EXTENDED RELEASE;ORAL | 019962-001 | Jan 10, 1992 | 3,876,802 | ⤷ Start Trial |
| Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | 5,840,684 | ⤷ Start Trial |
| Melinta Therap | TOPROL-XL | metoprolol succinate | TABLET, EXTENDED RELEASE;ORAL | 019962-001 | Jan 10, 1992 | 3,998,790 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Melinta Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 6517725 | ⤷ Start Trial |
| Japan | 2012501349 | ⤷ Start Trial |
| Hungary | S2100004 | ⤷ Start Trial |
| Canada | 2771879 | ⤷ Start Trial |
| South Korea | 20170039758 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2006042034 | ⤷ Start Trial |
| China | 102215858 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Melinta Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2337575 | C20160037 | Finland | ⤷ Start Trial | PRODUCT NAME: MIGALASTAAT;REG NO/DATE: EU/1/15/1082 31.05.2016 |
| 3214083 | LUC00196 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: DELAFLOXACINE OU UN DE SES SELS OU ESTERS, Y COMPRIS LA MEGLUMINE DE DELAFLOXACINE; AUTHORISATION NUMBER AND DATE: EU/1/19/1393 20191219 |
| 3214083 | C202130010 | Spain | ⤷ Start Trial | PRODUCT NAME: DELAFLOXACINO O UNA SAL O ESTER FARMACEUTICAMENTE ACEPTABLE DEL MISMO, INCLUYENDO DELAFLOXACINO MEGLUMINA.; NATIONAL AUTHORISATION NUMBER: EU/1/19/1393; DATE OF AUTHORISATION: 20191219; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1393; DATE OF FIRST AUTHORISATION IN EEA: 20191216 |
| 2337575 | 16C0039 | France | ⤷ Start Trial | PRODUCT NAME: ORITAVANCINE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES,TELS QUE LES SELS DIPHOSPHATES; REGISTRATION NO/DATE: EU/1/15/989 20150323 |
| 3214083 | 301091 | Netherlands | ⤷ Start Trial | PRODUCT NAME: DELAFLOXACINE, OF EEN ZOUT OF ESTERS ERVAN, MET INBEGRIP VAN DELAFLOXACINE MEGLUMINE; REGISTRATION NO/DATE: EU/1/19/1393 20191219 |
| 2337575 | CA 2016 00044 | Denmark | ⤷ Start Trial | PRODUCT NAME: ORITAVANCIN OG/ELLER FARMACEUTISKE SALTE HERAF, HERUNDER DIFOSFATSALTE; REG. NO/DATE: EU/1/15/989 20150323 |
| 3214083 | 5/2021 | Austria | ⤷ Start Trial | PRODUCT NAME: DELAFLOXACIN ODER EIN SALZ ODER ESTER DAVON, EINSCHLIESSLICH DELAFLOXACIN-MEGLUMIN; REGISTRATION NO/DATE: EU/1/19/1393 (MITTEILUNG) 20191219 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
